Quizartinib Doubles Overall Survival in FLT3-ITD-Positive AML ...Middle East

Medscape - News
The FLT3 inhibitor, taken during chemotherapy and continued as a single agent for up to 3 years, significantly improved survival compared with standard chemotherapy. Medscape Medical News

Hence then, the article about quizartinib doubles overall survival in flt3 itd positive aml was published today ( ) and is available on Medscape ( Middle East ) The editorial team at PressBee has edited and verified it, and it may have been modified, fully republished, or quoted. You can read and follow the updates of this news or article from its original source.

Read More Details
Finally We wish PressBee provided you with enough information of ( Quizartinib Doubles Overall Survival in FLT3-ITD-Positive AML )

Apple Storegoogle play

Last updated :

Also on site :

Most viewed in News


Latest News